In The Nick Of Time: Xbrane Picks Up Intas As Global Nivolumab Partner

Swedish Biosimilars Developer Beats Deal Deadline For Opdivo Rival

 
• By Dave Wallace
  
The deal was announced just days before Xbrane’s end-of-November deadline (Shutterstock)

More from Deals

More from Products